Abstract
The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anti-carbonic anhydrase, diuretic, hypoglycaemic, antithyroid, protease inhibitory and anticancer activity among others. A recently developed class of pharmacological agents incorporating primary sulfamoyl moieties in their molecule is constituted by the COX-2 selective inhibitors, with at least two clinically used drugs, celecoxib and valdecoxib. Another drug of this class, rofecoxib, does not contain sulfonamide moieties, but the isosteric and isoelectronic methylsulfone group. It was recently shown that the sulfonamide COX-2 selective inhibitors (but not the methylsulfone ones) also act as nanomolar inhibitors of several isozymes of the metallo-enzyme carbonic anhydrase (CA), some of which are strongly involved in tumourigenesis. In consequence, the potent anticancer effects of the sulfonamide COX-2 selective inhibitors and the much weaker such effects of rofecoxib, reported ultimately by many researchers, may be explained by the contribution of CA inhibition to such processes in addition to COX-2 inhibition.
Keywords: COX-2, CA inhibition, methylsulfone, metallo-enzyme, carbonic anhydrase, tumourigenesis
Mini-Reviews in Medicinal Chemistry
Title: COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents
Volume: 4 Issue: 6
Author(s): Claudiu T. Supuran, Angela Casini, Antonio Mastrolorenzo and Andrea Scozzafava
Affiliation:
Keywords: COX-2, CA inhibition, methylsulfone, metallo-enzyme, carbonic anhydrase, tumourigenesis
Abstract: The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anti-carbonic anhydrase, diuretic, hypoglycaemic, antithyroid, protease inhibitory and anticancer activity among others. A recently developed class of pharmacological agents incorporating primary sulfamoyl moieties in their molecule is constituted by the COX-2 selective inhibitors, with at least two clinically used drugs, celecoxib and valdecoxib. Another drug of this class, rofecoxib, does not contain sulfonamide moieties, but the isosteric and isoelectronic methylsulfone group. It was recently shown that the sulfonamide COX-2 selective inhibitors (but not the methylsulfone ones) also act as nanomolar inhibitors of several isozymes of the metallo-enzyme carbonic anhydrase (CA), some of which are strongly involved in tumourigenesis. In consequence, the potent anticancer effects of the sulfonamide COX-2 selective inhibitors and the much weaker such effects of rofecoxib, reported ultimately by many researchers, may be explained by the contribution of CA inhibition to such processes in addition to COX-2 inhibition.
Export Options
About this article
Cite this article as:
Supuran T. Claudiu, Casini Angela, Mastrolorenzo Antonio and Scozzafava Andrea, COX-2 Selective Inhibitors, Carbonic Anhydrase Inhibition and Anticancer Properties of Sulfonamides Belonging to This Class of Pharmacological Agents, Mini-Reviews in Medicinal Chemistry 2004; 4 (6) . https://dx.doi.org/10.2174/1389557043403792
DOI https://dx.doi.org/10.2174/1389557043403792 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Editorial [Hot Topic: Mechanisms of Drug Sensitivity and Resistance in Cancer (Guest Editor: Lorraine ODriscoll)]
Current Cancer Drug Targets Current and Emerging Therapeutic Approaches in HCV-Related Mixed Cryoglobulinemia
Current Medicinal Chemistry Targeting the G2/M Transition for Antitumor Therapy
Letters in Drug Design & Discovery Expression of Histone Acetyltransferase GCN5 and Histone Deacetylase 1 in the Cultured Mouse Preimplantation Embryos
Current Pharmaceutical Design The Role of Peptidyl Prolyl Isomerases in Aging and Vascular Diseases
Current Molecular Pharmacology Dasatinib in the Treatment of Chronic Myeloid Leukemia
Current Signal Transduction Therapy Growth Factors as Therapeutics for Diabetic Neuropathy
Current Drug Targets NBS1 Heterozygosity and Cancer Risk
Current Genomics Bypass Mechanisms of Resistance to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukaemia
Current Drug Discovery Technologies Recent Advances in the Chemistry of Phthalimide Analogues and their Therapeutic Potential
Mini-Reviews in Medicinal Chemistry Reduction of Hyperproduction of Thyroid Autoantibodies in Patients without Disturbance of the Thyroid Function: New Patents
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Biochemical Properties of Indoleamine 2,3-dioxygenase: From Structure to Optimized Design of Inhibitors
Current Medicinal Chemistry Drug-Related Cardiotoxicity for the Treatment of Haematological Malignancies in Elderly
Current Pharmaceutical Design The Management of Membranous Glomerulopathy in Allogeneic Stem Cells Transplantation: Updated Literature
Cardiovascular & Hematological Agents in Medicinal Chemistry Protein Kinase CK2 Inhibitors: Emerging Anticancer Therapeutic Agents?
Anti-Cancer Agents in Medicinal Chemistry Cell Proliferation and Cytotoxicity Assays
Current Pharmaceutical Biotechnology A Patent Review on the Use of L-Asparaginase in the Treatment of Acute Lymphocytic Leukemia
Recent Advances in Drug Delivery and Formulation A Targeted Therapy for Protein and Lipid Kinases in Chronic Lymphocytic Leukemia
Current Medicinal Chemistry Culture Supernatants from Lactobacillus plantarum Induce Necrosis on a Human Promyelocytic Leukemia Cell Line
Endocrine, Metabolic & Immune Disorders - Drug Targets Recent Advances in the Development of Novel Therapeutics Targeting Dendritic Cells
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued)